Previous 10 | Next 10 |
Aridis Pharmaceuticals (NASDAQ: ARDS ) has reached an agreement with the FDA to simplify its AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF). More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
SAN JOSE, Calif. , Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the U...
SAN JOSE, Calif. , Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong , Ph.D....
Aridis Pharmaceuticals (NASDAQ: ARDS ) : Q2 GAAP EPS of -$0.47 beats by $0.27 . More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN JOSE, Calif. , Aug. 11, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the...
SAN JOSE, Calif. , June 26, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong , Ph.D., Chi...
Aridis Pharmaceuticals's ( ARDS -3.0% ) AR-501 aerosols demonstrated to be well tolerated, with no serious adverse events, in phase 1 portion of Phase1/2a trial. More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
SAN JOSE, Calif. , June 22, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today positive results from the Phase 1 port...
SAN JOSE, Calif. , June 18, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it will participate in ...
SAN JOSE, Calif. , June 15, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed D...
News, Short Squeeze, Breakout and More Instantly...
Aridis Pharmaceuticals Inc. Company Name:
ARDS Stock Symbol:
NASDAQ Market:
Aridis Pharmaceuticals Inc. Website:
Biomerieux (BMXMF) is expected to report for Q1 2024 Conn's Inc. (CONN) is expected to report $-0.65 for Q1 2025 Cognetivity Neurosciences Ltd (CGNSF) is expected to report for quarter end 2024-04-30 Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q1 2024 China Jo-Jo ...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Commercial Metals Company (CMC) is expected to report $1 for Q3 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 GMS Inc. (GMS) is expected to report $2.04 for Q4 2024 China Jo-Jo Drugstores Inc. (CJJD) is expected to report for Q4 2024 Eiger BioPharmaceuticals Inc. (EIGR...